PMID- 36315313
OWN - NLM
STAT- MEDLINE
DCOM- 20230801
LR  - 20230803
IS  - 1591-9528 (Electronic)
IS  - 1591-8890 (Print)
IS  - 1591-8890 (Linking)
VI  - 23
IP  - 4
DP  - 2023 Aug
TI  - Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: a 
      meta-analysis of randomized controlled trials.
PG  - 1161-1169
LID - 10.1007/s10238-022-00920-2 [doi]
AB  - As an immunomodulatory agent with antitumor activity, lenalidomide has been 
      evaluated for its value in diffuse large B-cell lymphoma (DLBCL). We performed a 
      meta-analysis to gain a better understanding of the efficacy and safety of 
      lenalidomide in DLBCL. PubMed, Cochrane Library, and Embase were searched up to 
      March 2022 for potential studies. The pooled hazard ratio (HR) and relative risk 
      (RR) with 95% confidence interval (CI) were estimated by the fixed/random effects 
      model. Overall, 6 randomized controlled trials including 1938 patients were 
      included. The complete response rate (CRR) of the group containing lenalidomide 
      was 47.7% (95%CI 28.5-67.2%), which was higher than the 37.8% (95%CI 16.7-61.5%) 
      of the control group without lenalidomide (RR = 1.11, 95%CI 1.03-1.20, 
      P = 0.008). The overall estimation of survival showed a benefit for 
      progression-free survival (PFS) (HR = 0.77, 95%CI 0.66-0.90, P = 0.001) but not 
      overall survival (OS) or event-free survival (EFS). The lenalidomide group had a 
      significant incidence of grade >/= 3 hematological adverse events (AEs) involving 
      neutropenia (RR = 1.56, 95%CI 1.15-2.11, P = 0.004) and febrile neutropenia 
      (RR = 1.81, 95%CI 1.31-2.49, P < 0.001), with the incidence of neutropenia 
      (48.3%, 95%CI 37.5-59.1%) being highest. In conclusion, addition of lenalidomide 
      results in a higher CRR and better PFS but a higher incidence of grade >/= 3 
      hematological AEs involving neutropenia and febrile neutropenia.
CI  - (c) 2022. The Author(s).
FAU - Liu, Jia
AU  - Liu J
AD  - The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 
      Zhengzhou, China.
FAU - Mi, Ruihua
AU  - Mi R
AD  - The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 
      Zhengzhou, China.
FAU - Chen, Lin
AU  - Chen L
AD  - The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 
      Zhengzhou, China.
FAU - Guo, Xiaoli
AU  - Guo X
AD  - The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 
      Zhengzhou, China.
FAU - Liang, Taotao
AU  - Liang T
AD  - The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 
      Zhengzhou, China.
FAU - Yin, Qingsong
AU  - Yin Q
AD  - The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, 
      Zhengzhou, China. jnyinqingsong@163.com.
LA  - eng
GR  - LHGJ20220185/Joint project of Medical science and technology of Henan Province/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20221031
PL  - Italy
TA  - Clin Exp Med
JT  - Clinical and experimental medicine
JID - 100973405
RN  - F0P408N6V4 (Lenalidomide)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Humans
MH  - Lenalidomide/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Immunologic Factors/adverse effects
MH  - *Febrile Neutropenia
MH  - Antineoplastic Combined Chemotherapy Protocols
PMC - PMC10390621
OTO - NOTNLM
OT  - Clinical trials
OT  - Diffuse large B-cell lymphoma
OT  - Lenalidomide
OT  - Meta-analysis
COIS- The authors declare no competing interests.
EDAT- 2022/11/01 06:00
MHDA- 2023/08/01 06:44
PMCR- 2022/10/31
CRDT- 2022/10/31 12:17
PHST- 2022/08/12 00:00 [received]
PHST- 2022/10/11 00:00 [accepted]
PHST- 2023/08/01 06:44 [medline]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/10/31 12:17 [entrez]
PHST- 2022/10/31 00:00 [pmc-release]
AID - 10.1007/s10238-022-00920-2 [pii]
AID - 920 [pii]
AID - 10.1007/s10238-022-00920-2 [doi]
PST - ppublish
SO  - Clin Exp Med. 2023 Aug;23(4):1161-1169. doi: 10.1007/s10238-022-00920-2. Epub 
      2022 Oct 31.